Credit: Shutterstock photoMedpace Holdings, a global full-service CRO focused on small and mid-sized biopharmaceuticals, raised $161 million by offering 7 million shares at $23, the high end of the range of $20 to $23. Medpace Holdings plans to list on the Nasdaq under the symbol MEDP. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as lead managers on the deal.
The article Picking up the pace: Global CRO Medpace prices IPO at $23, the high end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
